Compare RVLV & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVLV | VIR |
|---|---|---|
| Founded | 2003 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2018 | 2019 |
| Metric | RVLV | VIR |
|---|---|---|
| Price | $23.91 | $8.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 7 |
| Target Price | ★ $29.73 | $19.43 |
| AVG Volume (30 Days) | 879.0K | ★ 1.6M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.64 | 17.49 |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $1,225,682,000.00 | $68,556,000.00 |
| Revenue This Year | $10.96 | $270.22 |
| Revenue Next Year | $8.01 | N/A |
| P/E Ratio | $52.52 | ★ N/A |
| Revenue Growth | ★ 8.48 | N/A |
| 52 Week Low | $17.35 | $4.25 |
| 52 Week High | $31.68 | $11.66 |
| Indicator | RVLV | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 45.69 | 46.47 |
| Support Level | $21.55 | $8.43 |
| Resistance Level | $26.79 | $10.10 |
| Average True Range (ATR) | 1.10 | 0.41 |
| MACD | -0.34 | 0.00 |
| Stochastic Oscillator | 5.38 | 37.74 |
Revolve Group Inc is an emerging e-commerce retailer, selling women's dresses, handbags, shoes, beauty products, and incidentals across its marketplace properties, Revolve and FWRD. The platform is built to suit the "next-generation customer," emphasizing mobile commerce, influencer marketing, and occupying an aspirational but attainable luxury niche. With $1.1 billion in 2024 net sales, the firm sits just outside the top 30 apparel retailers (by sales) in the U.S, but has consistently generated robust top-line growth as the industry continues to favor digital channels. Revolve generates approximately 18% of sales from private-label offerings, while focusing on building an inventory of distinctive products from emerging fashion brands with less than $10 million in annual sales.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.